Biologics
Bevacizumab
| Product | Strength / Concentration | Fill | PFS/Vial | BUD |
|---|---|---|---|---|
| Bevacizumab (Repackaged Avastin®) | 1.25mg/0.05mL | 0.07mL | PFS | 12 months |
As of May 2026
Orders &
Inquiries
Order Bevacizumab for Your Practice
Get pricing and availability for our repackaged bevacizumab pre-filled syringes designed for ophthalmic use.
Related Articles
May 1, 2023
Medivant Healthcare Announces Launch of Repackaged Bevacizumab (Avastin) for Ophthalmic Use
Medivant Healthcare announces the launch of repackaged Bevacizumab (Avastin) for ophthalmic use, offering precise dosing and consistent quality through automated prefilled syringe technology.
Read More
February 15, 2026
Medivant Healthcare to Attend ASRS 2026 Business of Retina Meeting
Medivant Healthcare will attend the ASRS 2026 Business of Retina Meeting in Houston, connecting with retinal professionals to support improved patient outcomes and practice efficiency.
Read More
April 25, 2026
Medivant Healthcare is proud to announce the launch of Andrela™
Medivant Healthcare is proud to announce the launch of Andrela™ the first 503B cGMP compounded microdose testosterone cypionate in prefilled syringes. Testosterone therapy is not one-size-fits-all. Individualized dosing at lower therapeutic levels demands a delivery format capable of matching clinical intent exactly — and until now, that format simply didn't exist.
Read MoreFrequently Asked Questions
Have questions? We have answers.